Tags

Type your tag names separated by a space and hit enter

Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study.
Hepatogastroenterology. 1992 Oct; 39(5):392-5.H

Abstract

We investigated the effect of octylonium bromide on a number of symptoms and functional aspects of the irritable bowel syndrome. Seventy-two patients complaining mainly of abdominal pain were studied in a double-blind trial (octylonium bromide 40 mg tid for 4 weeks or placebo). Clinical parameters were: abdominal pain, bloating and bowel frequency. Sigmoid manometry with simultaneous recording of the thresholds for distension and/or pain upon graded inflation of an endoluminal balloon was performed before and at the end of treatment. In contrast to placebo, octylonium bromide significantly reduced pain and bloating, and significantly increased (p < 0.02) the pain threshold throughout the treatment period. However, comparison with the placebo group failed to show any relevant differences. Neither treatment influenced the frequency of bowel movement. Sigmoid motility during distension was significantly reduced after octylonium bromide (p < 0.05), but it did not change after placebo. In conclusion, octylonium bromide is capable of reducing symptoms and motor reactivity of the sigmoid in patients with irritable bowel syndrome.

Authors+Show Affiliations

Servizio di Gastroenterologia, Policlinico S. Orsola, Bologna, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1459516

Citation

Baldi, F, et al. "Octylonium Bromide in the Treatment of the Irritable Bowel Syndrome: a Clinical-functional Study." Hepato-gastroenterology, vol. 39, no. 5, 1992, pp. 392-5.
Baldi F, Longanesi A, Blasi A, et al. Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study. Hepatogastroenterology. 1992;39(5):392-5.
Baldi, F., Longanesi, A., Blasi, A., Monello, S., Cestari, R., Missale, G., Corazziari, E., Badiali, G., Marzio, L., & Di Felice, F. (1992). Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study. Hepato-gastroenterology, 39(5), 392-5.
Baldi F, et al. Octylonium Bromide in the Treatment of the Irritable Bowel Syndrome: a Clinical-functional Study. Hepatogastroenterology. 1992;39(5):392-5. PubMed PMID: 1459516.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study. A1 - Baldi,F, AU - Longanesi,A, AU - Blasi,A, AU - Monello,S, AU - Cestari,R, AU - Missale,G, AU - Corazziari,E, AU - Badiali,G, AU - Marzio,L, AU - Di Felice,F, PY - 1992/10/1/pubmed PY - 1992/10/1/medline PY - 1992/10/1/entrez SP - 392 EP - 5 JF - Hepato-gastroenterology JO - Hepatogastroenterology VL - 39 IS - 5 N2 - We investigated the effect of octylonium bromide on a number of symptoms and functional aspects of the irritable bowel syndrome. Seventy-two patients complaining mainly of abdominal pain were studied in a double-blind trial (octylonium bromide 40 mg tid for 4 weeks or placebo). Clinical parameters were: abdominal pain, bloating and bowel frequency. Sigmoid manometry with simultaneous recording of the thresholds for distension and/or pain upon graded inflation of an endoluminal balloon was performed before and at the end of treatment. In contrast to placebo, octylonium bromide significantly reduced pain and bloating, and significantly increased (p < 0.02) the pain threshold throughout the treatment period. However, comparison with the placebo group failed to show any relevant differences. Neither treatment influenced the frequency of bowel movement. Sigmoid motility during distension was significantly reduced after octylonium bromide (p < 0.05), but it did not change after placebo. In conclusion, octylonium bromide is capable of reducing symptoms and motor reactivity of the sigmoid in patients with irritable bowel syndrome. SN - 0172-6390 UR - https://www.unboundmedicine.com/medline/citation/1459516/Octylonium_bromide_in_the_treatment_of_the_irritable_bowel_syndrome:_a_clinical_functional_study_ L2 - http://www.diseaseinfosearch.org/result/3876 DB - PRIME DP - Unbound Medicine ER -